Trials / Completed
CompletedNCT00054015
3-AP in Treating Patients With Advanced Prostate Cancer
A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Vion Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate cancer that has been previously treated with hormone therapy.
Detailed description
OBJECTIVES: * Determine the response rate in patients with advanced hormone-refractory prostate cancer treated with 3-AP. * Determine the toxic effects of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive 3-AP IV over 2 hours on days 1-4. Treatment repeats every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients are followed every 2-3 months for up to 1 year. PROJECTED ACCRUAL: Approximately 13-27 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | triapine |
Timeline
- Start date
- 2002-12-01
- Completion
- 2008-01-01
- First posted
- 2003-02-06
- Last updated
- 2013-11-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00054015. Inclusion in this directory is not an endorsement.